Patents by Inventor Yukiko Enya

Yukiko Enya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11981894
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: May 14, 2024
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
  • Patent number: 11655472
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: May 23, 2023
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuta Sunadoi, Reiko Waki, Kaname Muchima, Shin'ichi Takeda, Yoshitsugu Aoki
  • Publication number: 20230073008
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.
    Type: Application
    Filed: December 25, 2020
    Publication date: March 9, 2023
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Publication number: 20220333112
    Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 50 in the human dystrophin gene. The present specification provides an antisense oligomer which induces skipping of exon 50 in the human dystrophin gene.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 20, 2022
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuta SUNADOI, Reiko WAKI, Kaname MUCHIMA, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Publication number: 20220144902
    Abstract: A method for preparing myotubes in a non-invasive and simple manner and establishes an in vitro test system of an agent used for exon skipping therapy for muscular dystrophy. The method can prepare myotubes from urine-derived cells by introducing the MYOD 1 gene into urine-derived cells and exposing the urine-derived cells to at least one epigenetic regulatory compound.
    Type: Application
    Filed: December 25, 2018
    Publication date: May 12, 2022
    Inventors: Hotake TAKIZAWA, Yoshitsugu AOKI, Shin'ichi TAKEDA, Yukiko ENYA, Yuichiro TONE
  • Publication number: 20210147839
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: November 17, 2020
    Publication date: May 20, 2021
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Patent number: 10851373
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 1, 2020
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
  • Publication number: 20190040387
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: October 16, 2018
    Publication date: February 7, 2019
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Patent number: 10144931
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 4, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
  • Publication number: 20180265866
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: September 15, 2016
    Publication date: September 20, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • Publication number: 20090137790
    Abstract: The present invention relates to a method for producing an oligonucleic acid derivative characterized by using a phenoxyacetic acid derivative anhydride as an acylating agent and a pyridine derivative as the acylation reaction activator, in a capping step for protecting the 5?-hydroxyl group of a ribose of an oligonucleic acid derivative.
    Type: Application
    Filed: February 26, 2007
    Publication date: May 28, 2009
    Applicant: Nippon Shinyaku Co., Ltd.
    Inventor: Yukiko Enya